TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds
Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.14% | 78.63 | 1.2% | $618.81m | |
| AMGN | Amgen Inc. | 0.16% | 178.24 | 1.2% | $557.24m | |
| GILD | Gilead Sciences, Inc. | -0.22% | 67.38 | 0.9% | $542.96m | |
| BIIB | Biogen Inc. | 0.63% | 286.21 | 1.2% | $478.24m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.30% | 293.74 | 2.6% | $304.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.34% | 157.50 | 1.9% | $219.69m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.51% | 117.74 | 2.0% | $210.05m | |
| ILMN | Illumina, Inc. | -1.70% | 266.22 | 3.5% | $198.41m | |
| A | Agilent Technologies, Inc. | -1.50% | 63.16 | 1.5% | $196.40m | |
| NKTR | Nektar Therapeutics | -0.77% | 79.96 | 6.0% | $184.19m | |
| INCY | Incyte Corporation | 2.64% | 68.43 | 2.5% | $149.75m | |
| BMRN | BioMarin Pharmaceutical Inc. | 4.77% | 92.49 | 4.4% | $135.47m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.85% | 91.65 | 16.6% | $126.22m | |
| BLUE | Bluebird Bio, Inc. | 0.62% | 188.15 | 15.7% | $98.65m | |
| EXAS | Exact Sciences Corporation | -1.95% | 51.82 | 25.5% | $98.64m |
Company Profile
Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases. It specializes in molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. It offers product in clinical development is bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder, which is a type of female sexual dysfunction, defined as low desire with associated distress. It also offers drug candidates and development programs for cardiovascular diseases and inflammatory diseases. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.